Publications by authors named "J-M Berthelot"
Background And Objectives: Ocrelizumab (OCR), a humanized anti-CD20 monoclonal antibody, is highly efficient in patients with relapsing-remitting multiple sclerosis (RR-MS). We assessed early cellular immune profiles and their association with disease activity at treatment start and under therapy, which may provide new clues on the mechanisms of action of OCR and on the disease pathophysiology.
Methods: A first group of 42 patients with an early RR-MS, never exposed to disease-modifying therapy, was included in 11 centers participating to an ancillary study of the ENSEMBLE trial (NCT03085810) to evaluate the effectiveness and safety of OCR.
Multiple Sclerosis CSF Is Enriched With Follicular T Cells Displaying a Th1/Eomes Signature.
Neurol Neuroimmunol Neuroinflamm
November 2022
Background And Objectives: Tertiary lymphoid structures and aggregates are reported in the meninges of patients with multiple sclerosis (MS), especially at the progressive stage, and are strongly associated with cortical lesions and disability. Besides B cells, these structures comprise follicular helper T (Tfh) cells that are crucial to support B-cell differentiation. Tfh cells play a pivotal role in amplifying autoreactive B cells and promoting autoantibody production in several autoimmune diseases, but very few are known in MS.
View Article and Find Full Text PDFArticle Synopsis
- * There is a need for more research on the effectiveness of influenza and pneumococcal vaccines, as well as the COVID-19 vaccine, in preventing heart-related issues in HF patients; current guidelines recommend annual vaccinations.
- * To enhance vaccination rates among HF patients, a coordinated health policy involving various healthcare professionals is necessary, as implementation of existing vaccination recommendations has been lacking.